EYLEA HD® Injection: A Milestone in Treating Macular Edema
First and only FDA-approved treatment for retinal vein occlusion (RVO) indicated for up to every 8-week dosing after an initial monthly regimen.
Flexible Dosing Options for Enhanced Patient Care
The recent FDA approval for EYLEA HD® (aflibercept) Injection 8 mg is a major advancement. This treatment is specifically designed for patients suffering from macular edema following RVO. With a novel dosing schedule, patients can now receive injections as infrequently as every 8 weeks after an initial monthly dosing period. Moreover, an option for an every 4-week schedule is also available for patients who may need more frequent treatment depending on their specific circumstances.
Regeneron’s Commitment to Innovation
George D. Yancopoulos, M.D., Ph.D., co-Founder and Chief Scientific Officer at Regeneron, stated, "We believe these approvals further position EYLEA HD as a treatment of choice for certain retinal diseases, emphasizing our commitment to patients and retinal specialists. This pioneering approval potentially allows patients to reduce the frequency of injections by half compared to existing options."
Clinical Evidence from the QUASAR Trial
The FDA's approval was informed by data from the Phase 3 QUASAR trial, which evaluated the efficacy and safety of EYLEA HD as compared to its predecessor, EYLEA® (aflibercept) Injection 2 mg, in patients with RVO. Results from the trial demonstrated that EYLEA HD administered every 8 weeks achieved visual acuity gains comparable to those receiving EYLEA every 4 weeks. Notably, the drug showed consistent efficacy across different patient groups, including those with both branch retinal vein occlusions and central retinal vein occlusions.
Understanding Macular Edema and RVO
Retinal vein occlusion is a significant cause of vision loss in adults. It occurs when a blockage in the retinal vein hinders blood flow, resulting in conditions like macular edema where the retina swells due to fluid leakage. This condition is often driven by increased levels of a protein called vascular endothelial growth factor (VEGF), which promotes abnormal blood vessel growth in the eye.
Ongoing Commitment to Enhance Accessibility
Regeneron is deeply dedicated to ensuring that patients who require EYLEA HD can access their medication effectively. The EYLEA 4U program is designed to assist patients in understanding their insurance coverage and navigate financial support options. They can reach out by phone or visit the dedicated website for additional resources.
About the QUASAR Trial
The QUASAR trial, a global double-masked, active-controlled study, is pivotal in understanding the efficacy of EYLEA HD for treating macular edema due to RVO. Participants were divided into groups receiving different treatment regimens, allowing the study to effectively measure visual acuity changes over a 36-week period. This robust study design further solidifies EYLEA HD’s position in retinal therapy.
Broad Implications for Retinal Health
RVO, affecting millions worldwide, is not only a common retinal disease but also one that can lead to severe visual impairment if left untreated. With EYLEA HD now available, there is hope for improved outcomes among patients faced with this debilitating condition. By combining innovative medication with flexible dosing, Regeneron is setting new standards in vision care, ensuring that healthcare professionals have the tools they need to provide the best possible treatment for their patients.
Frequently Asked Questions
What is EYLEA HD® used for?
EYLEA HD® is approved for the treatment of macular edema following retinal vein occlusion, as well as other conditions like wet age-related macular degeneration, diabetic macular edema, and diabetic retinopathy.
How does the dosing schedule work?
Patients typically start with monthly injections and may shift to receiving EYLEA HD every 8 weeks after that, or they can choose to resume an every 4-week schedule depending on their individual health needs.
What were the key findings in the QUASAR trial?
In the QUASAR trial, EYLEA HD demonstrated comparable visual acuity gains to EYLEA at 4-week intervals, indicating its effectiveness in treating patients with RVO.
How can patients access their medication?
Patients can contact the EYLEA 4U program for assistance with understanding their insurance coverage and obtaining financial aid for their prescriptions.
Why is EYLEA HD considered innovative?
EYLEA HD is revolutionary as it reduces the frequency of injections needed by patients, while still maintaining efficacy, thus enhancing the overall patient experience.
